Should I buy or sell Salarius Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRX, but not buy additional shares or sell existing shares. View SLRX analyst ratings or view top-rated stocks .

How have SLRX shares performed in 2024?

Salarius Pharmaceuticals' stock was trading at $0.65 at the start of the year. Since then, SLRX stock has decreased by 22.4% and is now trading at $0.5044. View the best growth stocks for 2024 here .

Are investors shorting Salarius Pharmaceuticals?

Salarius Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 268,900 shares, an increase of 1,767.4% from the March 15th total of 14,400 shares. Based on an average daily trading volume, of 114,300 shares, the days-to-cover ratio is currently 2.4 days. Currently, 6.7% of the shares of the company are short sold. View Salarius Pharmaceuticals' Short Interest .

When is Salarius Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SLRX earnings forecast .

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its earnings results on Friday, March, 22nd. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $0.79.

What ETF holds Salarius Pharmaceuticals' stock?

Horizon Kinetics Medical ETF holds 31,094 shares of SLRX stock, representing 0.09% of its portfolio.

When did Salarius Pharmaceuticals' stock split?

Shares of Salarius Pharmaceuticals reverse split before market open on Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Arbutus Biopharma (ABUS) , Fulcrum Therapeutics (FULC) , Allena Pharmaceuticals (ALNA) , Biocept (BIOC) , DURECT (DRRX) , Dynavax Technologies (DVAX) and TG Therapeutics (TGTX) .

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SLRX

Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free SLRX Stock Alerts

$0.49

+0.01 (+2.08%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.48
▼
$0.52
50-Day Range: $0.45
▼
$0.68
52-Week Range: $0.43
▼
$2.31

Volume: 6,215 shs
Average Volume: 101,241 shs
Market Capitalization: $2.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Salarius Pharmaceuticals alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

SLRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLRX Stock News Headlines

April 2, 2024 | finance.yahoo.com

SLRX Pursues Important Goal

March 27, 2024 | msn.com

Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2024 | msn.com

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

March 23, 2024 | finanznachrichten.de

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 22, 2024 | sfgate.com

Salarius: Q4 Earnings Snapshot

March 22, 2024 | globenewswire.com

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 5, 2024 | msn.com

Quoin stock craters 47% on public offering after rallying in prior session

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 4, 2024 | msn.com

Quoin stock soars 60% on FDA update for ichthyosis drug

February 22, 2024 | markets.businessinsider.com

Salarius Pharmaceuticals Implements Cost-savings Measures

February 22, 2024 | msn.com

Salarius's CEO David Arthur steps down

February 22, 2024 | finance.yahoo.com

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

February 9, 2024 | uk.investing.com

Salarius Pharmaceuticals Inc (SLRX)

January 16, 2024 | finance.yahoo.com

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

January 13, 2024 | wsj.com

Square Pharmaceuticals Ltd.

January 3, 2024 | finance.yahoo.com

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

November 10, 2023 | finance.yahoo.com

SLRX Continues Work as it Seeks Alternatives

November 8, 2023 | morningstar.com

Salarius Pharmaceuticals Inc SLRX

November 7, 2023 | finance.yahoo.com

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

August 10, 2023 | bizjournals.com

Salarius Pharmaceuticals cuts half of workforce despite positive clinical developments

August 10, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 9, 2023 | finance.yahoo.com

SLRX Pursuing Strategic Alternatives

July 11, 2023 | benzinga.com

Watching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price Target

July 11, 2023 | finance.yahoo.com

SLRX Continues Cancer Fight with Phase I Trial Approval

July 11, 2023 | marketwatch.com

Salarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug Application

July 11, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

See More Headlines

Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SLRX
CUSIP: N/A
CIK: 1615219
Web: www.salariuspharma.com
Phone: (832) 834-6992
Fax: N/A
Employees: 2
Year Founded: 2011

Profitability

EPS (Most Recent Fiscal Year): ($4.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,540,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -197.96%
Return on Assets: -135.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.02
Quick Ratio: 5.02

Sales & Book Value

Annual Sales: $1.84 million
Price / Sales: 1.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.34 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 4,310,000
Free Float: 4,077,000
Market Cap: $2.07 million
Optionable: Not Optionable
Beta: 1.01

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. David J. Arthur M.B.A. (Age 61)
CEO, President & Director
Comp: $729.58k
Mr. Mark J. Rosenblum CPA (Age 71)
Executive VP of Finance & CFO
Comp: $409.98k
Dr. Nadeem Q. Mirza M.D.
M.P.H., Senior Vice President of Clinical Development
Dr. Daniela Y. Santiesteban
Director of Targeted Protein Degradation Program

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Sold 137,000 shares on 2/13/2024
Ownership: 2.234%

View All Institutional Transactions

SLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Salarius Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRX, but not buy additional shares or sell existing shares.
View SLRX analyst ratings or view top-rated stocks.
How have SLRX shares performed in 2024?: Salarius Pharmaceuticals' stock was trading at $0.65 at the start of the year. Since then, SLRX stock has decreased by 22.4% and is now trading at $0.5044.
View the best growth stocks for 2024 here.
Are investors shorting Salarius Pharmaceuticals?: Salarius Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 268,900 shares, an increase of 1,767.4% from the March 15th total of 14,400 shares. Based on an average daily trading volume, of 114,300 shares, the days-to-cover ratio is currently 2.4 days. Currently, 6.7% of the shares of the company are short sold.
View Salarius Pharmaceuticals' Short Interest.
When is Salarius Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SLRX earnings forecast.
How were Salarius Pharmaceuticals' earnings last quarter?: Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its earnings results on Friday, March, 22nd. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $0.79.

What ETF holds Salarius Pharmaceuticals' stock?: Horizon Kinetics Medical ETF holds 31,094 shares of SLRX stock, representing 0.09% of its portfolio.
When did Salarius Pharmaceuticals' stock split?: Shares of Salarius Pharmaceuticals reverse split before market open on Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Salarius Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).
How do I buy shares of Salarius Pharmaceuticals?: Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial